Novartis Q4 Results
Content
Click below to navigate
through the document
Novartis (continuing operations¹) 2024 full year guidance
Expected, barring unforeseen events; growth vs. PY in cc
↓
↑
Company overview
Financial review
Conclusions
Appendix
References
FINANCIAL PROFILE
Net sales expected
to grow
mid-single-digit
Key assumptions
Core operating income
expected to grow
high single-digit
FY 2024 guidance on
other financial KPIs
.
Core net financial result:
Expenses expected to be
around USD 0.6bn to 0.7bn
Core tax rate:
Expected to be around 16-16.5%
●
No US EntrestoⓇ Gx launch in 2024
1. As defined on page 37 of the Condensed Financial Report, Continuing operations include the retained business activities of Novartis, comprising the Innovative Medicines Division and the continuing Corporate activities. Core results and
constant currencies are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 49 of the Condensed Financial Report.
□ NOVARTIS | Reimagining Medicine.
Novartis Q4 Results | January 31, 2024
31View entire presentation